CRISPR Gene Correction Approaches for CBS/PSP

CRISPR-Cas gene editing technologies offer revolutionary potential for treating genetic forms of atypical parkinsonism. While clinical application remains years away, understanding these approaches helps patients and families make informed decisions about research participation and future therapeutic options.

Overview

CRISPR-Cas gene editing technologies offer revolutionary potential for treating genetic forms of atypical parkinsonism. While clinical application remains years away, understanding these approaches helps patients and families make informed decisions about research participation and future therapeutic options.

Overview

Gene editing uses molecular tools to directly modify DNA sequences, potentially correcting disease-causing mutations or modulating gene expression. For CBS and PSP, which involve tau pathology (4R-tauopathy), several genetic targets are relevant, including MAPT (tau gene), GBA (glucocerebrosidase), and GRN (progranulin)[@guo2024].

CRISPR Technologies

CRISPR-Cas9

The original CRISPR system uses Cas9 endonuclease to create double-strand breaks at targeted genomic locations.

Components:

• Guide RNA (gRNA): Directs Cas9 to specific genomic sequence
• Cas9 protein: Creates double-strand break
• Repair template: Provides corrected sequence for homology-directed repair

• Double-strand breaks can cause unintended edits
• Requires break and repair process
• Large size of Cas9 limits delivery options

Base Editing

Base editing allows precise single-nucleotide changes without double-strand breaks.

Types:

• Cytosine base editors (CBE): Convert C→T
• Adenine base editors (ABE): Convert A→G
• Glycosylase base editors: Expanded targeting

• No double-strand breaks
• Precise single-nucleotide changes
• Reduced off-target effects

• Correcting MAPT P301L mutation
• Modifying GBA variants
• Creating protective APOE variants

Prime Editing

Prime editing uses Cas9 fused to reverse transcriptase for precise insertions, deletions, and substitutions.

Advantages:

• All types of edits possible
• No double-strand breaks required
• Greater precision than standard CRISPR

• Larger construct size
• Lower efficiency
• Delivery challenges

Target Genes for CBS/PSP

MAPT (Tau Gene)

Mutations:

• P301L, P301S: Cause familial PSP
• K257T, G389R: Cause CBD-like syndrome

• Correct disease-causing mutations
• Disrupt cryptic splicing sites
• Reduce expression of mutant allele

GBA (Glucocerebrosidase)

Variants:

• N370S, L444P: Increase PD/CBS risk
• Null variants: Severe deficiency

• Correct pathogenic variants
• Enhance GBA expression
• Reduce substrate accumulation

GRN (Progranulin)

Mutations:

• Null mutations cause FTD
• May modify CBS/PSP risk

• Restore expression
• Correct splice mutations
• Increase progranulin levels

Delivery Methods

AAV Vectors

Advantages:

• Long-term expression (years)
• Non-pathogenic
• Wide clinical use

• Small cargo capacity (~4.7 kb)
• Pre-existing immunity common
• Limited tissue targeting

• AAV9: Neuronal transduction
• AAV-PHP.B: Enhanced CNS penetration
• AAV2: Established safety profile

Lipid Nanoparticles (LNPs)

Advantages:

• Larger cargo capacity
• No pre-existing immunity
• Repeat dosing possible

• COVID vaccines demonstrated safety
• CNS delivery being optimized
• mRNA delivery established

Viral Vectors

| Vector | Cargo Capacity | Duration | Immunogenicity |
|--------|---------------|----------|-----------------|
| AAV | ~4.7 kb | Years | Low-moderate |
| Lentivirus | ~8 kb | Stable | High |
| Adenovirus | ~36 kb | Short-term | High |

Current Research Status

Preclinical Progress

• In vitro models: iPSC-derived neurons from patient cells
• Animal models: Mouse models of tauopathy
• Proof-of-concept: Successful editing in mouse brain

Clinical Trials

• Clinical trials ongoing: Base editing for sickle cell, transthyretin amyloidosis
• CNS trials: Limited but expanding
• Timeline: CNS gene therapy 5-10 years away for CBS/PSP

Challenges

Ethical Considerations

Somatic vs Germline Editing

Somatic Editing:

• Only patient cells affected
• Changes not passed to offspring
• Currently preferred approach
• Lower ethical concern

• Affects embryos/germ cells
• Changes inherited by future generations
• Currently not clinically appropriate
• Higher ethical concern

Informed Consent

Requirements:

• Understanding long-term uncertainties
• Risk of unintended edits
• Possibility of no direct benefit
• Alternative treatment options

Access and Equity

Concerns:

• High cost may limit access
• Development priorities may favor common diseases
• Need for diverse population representation in trials

Future Directions

Enhanced Delivery

• Novel AAV capsids for CNS
• Targeted LNPs crossing BBB
• Exosome-based delivery

Precision Medicine

• Patient-specific guide RNAs
• Allele-specific editing
• Combination with other modalities

Regulatory Pathway

• FDA guidance for gene editing
• Accelerated approval pathways
• Real-world evidence integration

Cross-Linking

• [Personalized Treatment Plan - Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)](/therapeutics)
• [MAPT Gene](/genes/mapt)](/genes)
• [GBA Gene](/genes/gba)](/genes)
• [GRN Gene](/genes/grn)](/genes)
• [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)

See Also

• [ClinicalTrials.gov - Gene Therapy](https://clinicaltrials.gov/)
• [ASHGene - Gene Editing Resources](https://www.ashg.org/)](/resources)
• [NIH Gene Editing Research](https://www.genome.gov/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CRISPR Gene Correction Approaches for CBS/PSP discovered through SciDEX knowledge graph analysis: